Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with bullous pemphigoid treated with IL-2 had ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Bullous pemphigoid is a rare autoimmune disease that affects your skin. It’s a chronic disease that causes itchy, fluid-filled blisters to form all over your body. Although people of all ages, ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP), a ...